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Charcot–Marie–Tooth disease (CMT) comprises a clinically andgenetically heterogeneousgroupof peripheral
neuropathiescharacterizedbyprogressivedistalmuscleweaknessandatrophy, footdeformitiesanddistal sen-
sory loss. Following the analysis of two consanguineous families affected by amedium to late-onset recessive
formof intermediateCMT,we identifiedoverlapping regionsof homozygosity onchromosome1p36with a com-
bined maximum LOD score of 5.4. Molecular investigation of the genes from this region allowed identification
of two homozygous mutations in PLEKHG5 that produce premature stop codons and are predicted to result
in functional null alleles. Analysis of Plekhg5 in the mouse revealed that this gene is expressed in neurons
and glial cells of the peripheral nervous system, and that knockout mice display reduced nerve conduction vel-
ocities that are comparable with those of affected individuals from both families. Interestingly, a homozygous
PLEKHG5missense mutation was previously reported in a recessive form of severe childhood onset lower
motor neuron disease (LMND) leading to loss of the ability to walk and need for respiratory assistance.
Together, these observations indicate that different mutations in PLEKHG5 lead to clinically diverse outcomes
(intermediate CMT or LMND) affecting the function of neurons and glial cells.
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INTRODUCTION
Hereditary motor and sensory neuropathy (HMSN), also known
as Charcot–Marie–Tooth disease (CMT), is the most frequent
inherited neurological disorder with a prevalence of 1 in 2500
(1). CMT affects both sensory and motor peripheral nerves and
is clinically characterized by distal and symmetric muscle
atrophy in lower limbs and hands, foot deformities, distal
sensory loss and decreased or absent tendon reflexes (2,3). Two
major types have been distinguished on the basis of electrophysio-
logical criteria: a demyelinating form (HMSN type I or CMT1)
with motor nerve conduction velocities (MNCVs) of the median
nerve lower than 38 m/s and an axonal form (HMSN type II or
CMT2) in which MNCVs are normal or only slightly reduced
(.40 m/s), while amplitudes of motor and sensory action poten-
tials are significantly decreased (4–6). Histological features
reflect these findings: in CMT1, peripheral nerve pathology
shows defects of myelinating Schwann cells (SC), responsible
for decreased nerve conduction, whereas in CMT2 the number
of large caliber axons is reduced, leading to decreased motor
and sensory action potentials. A third group of CMTs with
MNCVs between 25 and 45 m/s is considered as intermediate
(5,7,8). In this group of CMTs, histology shows the coexistence
of glial (demyelination, onion bulb formation) and axonal (degen-
eration of large caliber axons and regenerative sprouting) defects
(9,10).
While recent progress has allowed identification of more than
40 genes in various forms of CMT, there is still a relatively large
fraction of cases for which molecular diagnosis cannot be estab-
lished (11). As part of the effort to identify additional
CMT-causing genes, we analyzed two consanguineous multi-
plex families presenting with an autosomal-recessive form of
intermediate CMT and identified two homozygous mutations
in PLEKHG5. These genetic data together with the characteriza-
tion of the mice with disrupted Plekhg5 clearly indicate that in
addition to previously reported lower motor neuron disease
(LMND) (12), mutations in PLEKHG5 are also causing an inter-
mediate CMT.
RESULTS
Identification of mutations in PLEKHG5 in two families
affected with an intermediate CMT
Two consanguineous multiplex families affected by an
autosomal-recessive form of intermediate CMT were studied.
The first family (221) originated from Portugal and comprised
two affected and four unaffected siblings born to healthy
parents who were first cousins. In the second family (NP72) of
Moroccan origin, four out of eight siblings born to healthy
parents with first-degree consanguinity were affected. Affected
individuals had limb muscle weakness and atrophy, foot deform-
ities, moderately decreased nerve conduction velocities, loss of
large myelinated fibers and thin myelination seen on nerve
biopsy (Fig. 1, Table 1). No signs of brain involvement were
observed. In four of the five characterized affected individuals,
the age of onset was between the second and fifth decade and
one patient had earlier disease onset at the age of 7 years.
To identify the gene responsible for this characteristic form of
recessive CMT, we performed genome-wide homozygosity
mapping in both families. In family 221, microsatellite genotyp-
ing was performed with a set of 400 markers from the
ABI-Prism linkage mapping set v2 revealing a few regions of
homozygosity in the affected individuals, including an
10 Mb region at the 1p-telomere (Fig. 1 and Supplementary
Material, Fig. S1). For family NP72, we used a set of 600
000 SNPs from the Illumina Human 660W-Quad array and
mapping identified only one homozygous region genome-wide.
This was a 1.52 Mb stretch on chromosome 1, which was
common to all affected individuals and absent in the healthy
members of the pedigree. Haplotype reconstruction revealed
that two ancestral recombination events delimited the autozy-
gous region in this latter family (Fig. 1). The 1.52 Mb autozy-
gous region identified in family NP72 completely overlapped
with the chromosome 1p-tel region of interest found in family
221. Combined parametric multipoint linkage analysis in both
families [Merlin software (13), autosomal-recessive inherit-
ance] confirmed these findings and assigned a max LOD score
of 5.4 (LODmax ¼ 1.9 and 3.5 for families 221 and NP72, re-
spectively) to the shared region of homozygosity (Supplemen-
tary Material, Fig. S1). The critical interval contained 25
annotated genes (Fig. 2). Further analysis revealed that, accord-
ing to data that we had generated previously (14), only two of
them, PLEKHG5 (MIM 611101) and GPR153 (MIM 614269),
had an expression profile compatible with genes playing a
role in peripheral nerve development and function. Their
Sanger sequencing (including coding exons and flanking intron-
ic regions) in affected subjects revealed a homozygous 1 bp de-
letion in exon 3 of PLEKHG5 (NM_198681.3:c.269delC) in
family 221 leading to a frameshift and premature termination
codon (NP_941374.2:p.Pro90Hisfs∗45) and a homozygous
7 bp duplication (NM_198681.3:c.1143_1149dup [tgaagac])
in exon 10 of PLEKHG5 directly introducing a stop codon
(NP_941374.2:p.Glu384∗) in family NP72 (Fig. 2). Parents
for whom the DNA was available were heterozygotes for the
mutations, and unaffected siblings were either heterozygotes
or presented no mutations (Fig. 1). Neither c.269delC nor
c.1143_1149dup were detected in controls (79 North African
and 339 European, and 100 North African and 49 European
subjects, respectively). Moreover, these mutations were
absent from the dbSNP and the Exome Sequencing Project
databases.
Pattern of expression of Plekhg5 suggests its role
in neurons and glial cells
PLEKHG5 was previously shown to be expressed in human
spinal cord, brain and peripheral nerves (12), while the expres-
sion of its mouse and rat orthologue, Plekhg5, was detected in
the brain (15,16). We have confirmed and extended these find-
ings using samples from various regions of adult (2-month-old)
mouse nervous system. Quantitative PCR data revealed the
highest level of expression of Plekhg5 in the brain and in the
sciatic nerve endoneurium (Fig. 3A). Interestingly, the endo-
neurial expression of Plekhg5 was dynamically regulated
during development with the highest level at postnatal days
10–14 (Fig. 3B). This expression profile suggested its role in
PNS myelination (14,17). We therefore evaluated the expression
of Plekhg5 in SC and found that both primary purified mouse SC
and the mouse SC line MSC80 expressed Plekhg5 (Fig. 3C). The
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temporal and spatial expression pattern of Plekhg5 in neurons
and glial cells is in agreement with its possible role in the patho-
physiology of an intermediate CMT subtype affecting both
neurons and SC.
Plekhg5DEx11-Ex17/DEx11-Ex17mice develop mild neuropathy
In order to gain insight into the consequences of disrupted
PLEKHG5 function, we decided to use recently generated
Figure 1.Characterization of two families affected with an intermediate form of CMT. (A) Haplotype reconstruction for 20 SNPs and 12 microsatellite markers of the
chromosome 1p36 region in families 221 and NP72. Microsatellite and SNP markers are ordered from telomere (top) to centromere (bottom) and show overlapping
segments of autozygosity. Deduced haplotypes of the mother of the siblings in family 221 are bracketed. The critical region of segregation is defined by ancestral
recombination events revealed by haplotype reconstruction in family NP72.+, wild-type allele; -, mutation. (B) Pes cavus deformity is evident in both affected indi-
viduals from family 221. The distal amyotrophy is more pronounced in lower than in upper limbs. (C) Transverse section of sural nerve biopsy sample of individual
NP72.5 (Thionin-stained semi-thin section of a glutaraldehyde fixed, osmium tetroxidepost-fixed, epon-embedded nerve biopsy specimen; ×400 magnification).
Most axons are surrounded by a disproportionally thin myelin sheath. In addition, myelinated nerve fiber density is reduced to about 70% of normal with predominant
loss of larger fibers.
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Plekhg5DEx11-Ex17/DEx11-Ex17 mice (18). These animals were pro-
duced by a cross between animals with loxP sites flanking exons
11–17, which contain the RhoGEF catalytic domain considered
as a main functional domain of Plekhg5, and a small portion of
the PH domain [Fig. 4A, Supplementary Material, Fig. S2
(15,16)] with mice expressing Cre recombinase in their germline
[CAG-Cre transgenic mice (19)], thus leading to excision of
the targeted region in all mouse tissues, as verified by genomic
PCR and RT-PCR (Supplementary Material, Fig. S2).
Plekhg5DEx11-Ex17/DEx11-Ex17 mice developed normally, without
any major phenotype up to adulthood (including the absence of
clear neurological symptoms such as tremor, gait instability or
changes in open field activity).
We therefore used a combination of electrophysiological and
behavioral tests in order to evaluate possible changes in PNS
function in Plekhg5 knockout mice. Electrophysiological evalu-
ation revealed that the MNCV was reduced in 6- and
12-month-old Plekhg5DEx11-Ex17/DEx11-Ex17 mice (Fig. 4B) and
both proximal and distal compound action potentials (CAPs)
were delayed in affected animals at the age of 12 months, while
only proximal CAPs were affected at the age of 6 months
(Fig. 4C). The reduced velocity (6 m/s) was compatible
with the relatively mild decrease in MNCVs observed in CMT
subjects. Plekhg5DEx11-Ex17/DEx11-Ex17 mice were then assessed
with the rotarod to test their motor performances. While the
affected animals performed slightly less well than control
Table 1. Summary of clinical findings in families NP72 and 221
Family NP72 221
Patient NP72.4 NP72.5 NP72.9 221.13 221.17
Gender M F M M F
Age at onset (years) 28 44 30 7 20
Age at last examination (years) 43 53 47 51 42
Distal weakness
ULa + ++ ++ ++ +
LLb ++ +++ +++ ++ +
Distal muscle atrophyc
UL ++ ++ ++ ++ 2
LL +++ ++ ++ ++ 2
Involvement of proximal musclesd
UL 2 + + + 2
LL 2 ++ + + 2
Foot deformitye +/ht NA +/ht +/ht +
General stage of disabilityf 3 7 4 4 2
Distal sensory lossg + + NA + +
Spine deformityh 2 2 2 + +
Deep tendon reflexesi 2/2 2/2 2/2 2/2 (+)/2
Motor nervesj
Median (≥48/≥8) 39/4.2 ND 35/3.7 36/8.8 39/8.5
Ulnar (≥48/≥8) ND ND 35/6.5 34/5.3 33/7.4
Peroneal (≥42/≥5) 29/0.8 ND 27/2.1 NR 29/3.5
Tibial (≥40/≥8) 28/6.3 ND 26/2.5 31/1.0 26/8.8
Sensory nervesk
Median (≥45/≥12) ND ND 36/21 40/6 42/17
Ulnar (≥50/≥15) 35/14.3 ND 30/13 37/19 37/10
Superficial peroneal (≥40/≥10) 30/0.7 ND ND NR 25/9
Sural (≥42/≥10) 32/2 ND NR ND ND
Sural nerve biopsy ND Demyelinating and axonal changes NAl NA ND
Muscle biopsy ND ND Neurogenic muscle atrophy NA ND
UL, upper limbs; LL, lower limbs; NA, no data available; ND, not done.
aWrist extension: 2¼ no weakness; + ¼ 4/5 on MRC scale; ++ ¼ ,4/5 on MRC scale; +++ ¼ complete paralysis.
bAnkle dorsiflexion: 2¼ no weakness; + ¼ 4/5 on MRC scale; ++ ¼ ,4/5 on MRC scale; +++ ¼ complete paralysis.
c2¼ not affected; + ¼ mild atrophy; ++ ¼ moderate atrophy; +++ ¼ severe atrophy.
d2¼ not affected; + ¼ mild; ++ ¼ severe.
e2¼ no deformity; + ¼ pes cavus; ++ ¼ clubfoot deformity; +++ ¼ surgery required, ht ¼ hammer toes.
f0 ¼ normal, 1 ¼ normal walkingand runningbut fatigabilityand cramps,2 ¼ normal walking, runningand jumping impossible, 3 ¼ abnormalwalkingwithout help,
4 ¼ abnormal walking only with simple canes, 5 ¼ abnormal walking only with crutches, 6 ¼ abnormal walking only with a walker, 7 ¼ wheelchair-bound,
8 ¼ bedridden.
g2normal sensibility; + ¼ decreased sensibility; ++ ¼ absent sensibility.
h2¼ none; + ¼ mild; ++ ¼ severe; +++ ¼ surgery required.
iUpper/lower extremities; + ¼ normal; (+) ¼ decreased;2 ¼ areflexia.
jMotor nerve conduction velocities (in m/s)/amplitudes of compound motor action potentials (in mV); normal values are given in brackets following the nerve’s name;
NR, not recordable.
kSensory nerveconductionvelocities (inm/s)/sensorynerve actionpotentials (inmV); normal valuesare given inbrackets followingthe nerve’s name;NR, not recordable.
lThe biopsy specimens could not be evaluated due to severe traction/fixation artifacts.
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littermates, this difference did not reach statistical significance
(Fig. 4D).
Plekhg5DEx11-Ex17/DEx11-Ex17mice do not develop lower
motor neuron disease
Although clinical characterization of families 221 and NP72
corresponded to an intermediate CMT phenotype, previous data
indicated that a missense mutation in PLEKHG5 leads to a
severe form of LMND (12). Thus, we characterized more
detail a-motoneurons and neuromuscular junctions (NMJs) in
Plekhg5DEx11-Ex17/DEx11-Ex17 animals (Fig. 5, Supplementary
Material, Fig. S3). Characterization of ventral horn a-
motoneurons of the lumbar spinal cord of 6- and 12-month-old
Plekhg5DEx11-Ex17/DEx11-Ex17 mice failed to reveal any differences
in their number or morphological characteristics (Fig. 5A–C;
Supplementary Material, Fig. S3). In addition, we did not observe
any significant change in the pattern of innervation, change in
the NMJ shape or any denervation in the soleus or extensor digi-
torum longus (EDL) muscles of Plekhg5DEx11-Ex17/DEx11-Ex17
mice (Fig. 5D, Supplementary Material, Fig. S3). The absence
of changes in a-motoneurons and in NMJ indicated that
during the analyzed period (up to 1 year of age), the
Plekhg5DEx11-Ex17/DEx11-Ex17 mice did not develop detectable
signs of LMND.
DISCUSSION
It is presently unknown why some PLEKHG5 mutations lead to
an intermediate CMT neuropathy in humans and mice while
others cause severe LMND in affected individuals. The homozy-
gous missense mutation identified in the African family affected
by LMND results in an amino acid substitution (p.Phe647Ser) in
the pleckstrin homology domain (PH domain, Fig. 4) of
PLEKHG5, which affects its subcellular localization and func-
tion (12). On the other hand, mutations in CMT families 221
and NP72 most likely result in critically truncated or no
protein at all (due to nonsense-mediated decay). The in-frame
deletion in the mouse model is also likely to represent a non-
functional null allele as it removes the entire Rho guanine nu-
cleotide exchange factor (GEF) catalytic domain that is essential
for Plekhg5 to regulate RhoGTPase signaling (15,16).
Importantly, it was previously observed that defects in other
GEFs affect the PNS function. Mutations in FGD4 (MIM
611104) lead to demyelinating Charcot–Marie–Tooth disease
CMT4H (MIM 609311) (20–22), while a missense mutation
in ARHGEF10 (Rho guanine nucleotide exchange factor 10;
MIM 608136) results in an autosomal-dominant trait with
slowed NCV without clinical manifestation (23).
Recent data also indicate that PLEKHG5 may interact with a
variety of partners including multiple PDZ domain protein 1
Figure 2. PLEKHG5 mutations identified in families 221 and NP72. The autozygous region on chromosome 1 common to both families (vertical red bar) contains
25 genes (horizontal black bars), including PLEKHG5 (horizontal red bar). Chromatograms of DNA from the index case of each family, detailing the mutations
identified, are presented, along with control sequences. Genomic structure of PLEKHG5 and nucleotide numbering is based on reference sequence
NM_198681.3. Amino acid numbering is based on reference sequence NP_941374.2.
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[MUPP1 or MPDZ; MIM 603785 (24,25)], in particular through
its PDZ-binding motif that is lost in families 221 and NP72.
MUPP1 is one of the proteins involved in epithelial-like
polarization of SC (26,27), which is critical for both radial and
longitudinal extension of their myelin sheaths (26,28). It is there-
fore possible that disturbed interactions between PLEKHG5 and
Figure3.Plekhg5 expression in mouse nervous system. (A) The relative level of Plekhg5 expression was evaluated by quantitative PCR (qPCR) in dorsal root ganglia
(DRG), brain, optic nerve, spinal cord and sciatic nerve endoneurium. mRNA levels are presented as fold change over the mRNA level in the DRG. The data represent
the mean+SD of triplicate measurements. (B) Relative mRNA levels of Plekhg5 were determined by qPCR and microarrays (E17, P0, P2, P4 and P10: whole mouse
sciatic nerve; P14, P28 and P56: sciatic nerve endoneurium). For each time point, the mRNA levels are presented as fold increase over the mRNA level at E17.5 (for
qPCR measurements) or at P0 (for microarray experiments). The qPCR data represent the mean+SD of triplicate measurements. (C) Relative mRNA levels of
Plekhg5 were determined by qPCR in purified mouse Schwann cells (mSCs) and in the mouse SC line (MSC80). The data are represented as fold change over the
mRNA levels in mSCs. The presented qPCR results were normalized using Ube2l3 as the reference gene.
Figure 4.Disruption of Plekhg5 function in mice leads to mild neuropathy. (A) Schematic diagram showing the targeted Plekhg5 allele (based on Ensembl transcript
ENSMUST00000118648). Homologous recombination between two loxP sites (black arrowheads positioned between exons 10–11 and 17–18) led to the deletion of
exons 11–17 which contain the complete Rho-GEF domain and a small portion of the pleckstrin homology (PH) domain. The deletion of exons 11–17 (816 nucleo-
tides) does not disrupt the reading frame of the truncated mRNA. The position of the previously described missense mutation (12) is indicated as well as the positions of
mutations identified in this study. RBD: Ras binding domain; PDZ: Psd95-Dlg1-Zo1 domain (B) Electrophysiological characterization of 6- and 12-month-old
wild-type (WT, Plekhg5+/+) and knockout (KO, Plekhg5DEx11-Ex17/DEx11-Ex17) animals revealed reduced motor nerve conduction velocity (MNCV) in affected
mice (n ¼ 4–5). (C) Both proximal CAP and distal CAP were delayed in affected animals. (D) Knockout mice exhibit deficits in rotarod performance test;
however, the observed difference does not reach statistical significance. Error bars: SEM, statistically significant differences are indicated by ∗ (P , 0.05).
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its partners could contribute to some of the CMT phenotypes
present in families 221 and NP72.
Finally, it was also previously shown that PLEKHG5 is able to
activate the nuclear factor kB (NF-kB) signaling pathway (12).
Activation of NF-kB signaling pathway was previously shown to
play critical roles in both neurons/axons (29) and in SC biology
(30). It is therefore possible that disturbed NF-kB signaling con-
tributes to neuronal and/or glial phenotypes caused by mutations
in PLEKHG5.
To conclude, our results reveal that in addition to severe
LMNDs, PLEKHG5 mutations can also lead to intermediate
CMT. While further data are needed, the above-mentioned
observations indicate that PLEKHG5 is involved in both glial
and neuronal function. Therefore, this gene should be considered
in genetic diagnosis in families with clinical pictures compatible
with CMT or LMNDs.
MATERIAL ANDMETHODS
Web resources
Online Mendelian Inheritance in Man (OMIM), http://www.om
im.org/.
dbSNP, http://www.ncbi.nlm.nih.gov/SNP.
Exome Variant Server, http://evs.gs.washington.edu/EVS/.
Marshfield Center, http://research.marshfieldclinic.org/genetics.





Genotyping and linkage analyses
After informed consent was given, blood samples from selected
members of the Moroccan and the Portuguese families were
obtained. Genomic DNA was extracted using standard proce-
dures. To identify the disease locus in family 221, we perform
a genome-wide mapping using 400 microsatellites, spaced
10 cM apart on all chromosomes (ABI-Prism linkage mapping
set v2; Applied Biosystems). Several additional microsatellite
markers were used to further delimitate the critical interval of
segregation of the disease locus. Polymerase chain reaction
(PCR) fragments were resolved on an ABI-3730 sequencer
(Applied Biosystems) and genotypes were determined with
GeneMapper-3.5 (Applied Biosystems). In family NP72, a
genome-wide SNP genotyping was carried out using Illumina
660W-Quad microarrays (Illumina). Linkage analyses in
family 221 were performed with ALLEGRO 1.2c (31) and in
addition we used Merlin 1.1.2 (13) for linkage in both families,
with the following parameters: the disease was considered to
be a fully penetrant autosomal-recessive trait, with a disease
allele frequency of 0.001 in the population and equal
Figure 5. Disruption of Plekhg5 function does not lead to detectable defects in motoneurons or NMJ. (A) Characterization of lumbar a-motoneurons in
Plekhg5DEx11-Ex17/DEx11-Ex17 mice at the age of one year. No difference in the number (B) or size (C) of a-motoneurons (MN) per ventral horn was detected
between control (WT, Plekhg5+/+) and affected (KO, Plekhg5DEx11-Ex17/DEx11-Ex17) animals. (D) Confocal images of presynaptic nerve terminals (detected with
a-neurofilament antibodies, in green) and postsynaptic endplates (detected witha-bungarotoxin CF594, in red). We did not observe obvious structural abnormalities
in the soleus and EDL muscles of Plekhg5 deficient animals.
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recombination fractions for male and female individuals. We
assigned equal frequencies to the alleles observed in both fam-
ilies. For microsatellite markers, genetic distances were taken
from the Marshfield Center (http://research.marshfieldclinic.
org/genetics) according to the human genome map [available
from National Center of Biological Investigation (http://www.
ncbi.nlm.nih.gov), Ensembl (http://www.ensembl.org) and
UCSC (http://genome.ucsc.edu)]. Homozygosity mapping
for family NP72 was performed using HomozygosityMapper
[http://www.homozygositymapper.org; (32)]. In order to
combine both microsatellite and SNP markers to calculate a
joined LOD score under Merlin software, we used the Rutgers
Map V3 (GRCh37 patch 4: a third-generation combined linkage-
physical map of the human genome) as well as DeCode Map and
UniSTS data banks.
DNA sequencing
Primers were designed using Oligo6 (MBI; Molecular Biology
Insights, Inc.) to amplify all coding exons of the candidate
genes, including exon–intron boundaries. Both strands of the
PCR products were subjected to Sanger sequencing with
BigDye Terminator chemistry V3.1 (Applied Biosystems) on
an ABI 3730 sequencer. Sequence chromatograms were ana-
lyzed using SeqScape software version 2.5 (Applied Biosys-
tems).
Plekhg5DEx11-Ex17/DEx11-Ex17mice genotyping
Plekhg5DEx11-Ex17/DEx11-Ex17 and control (Plekhg5+/+) mice
were genotyped by two separate PCRs amplifying the WT
allele and the knockout allele. Primer combinations conKO2/
conKO4 and conKO2/ApaIRA were used for amplifying the
WT and null alleles, respectively. Primer sequences are avail-
able upon request.
Quantitative PCR
Total RNA was isolated from adult (2-months-old) wild-type
mice dorsal root ganglia, brain, optic nerve and spinal cord,
from sciatic nerves isolated at various developmental time
points (E17-P56), from purified mouse SC and MSC80 cells as
previously described (33). Two hundred and fifty to 500 ng of
total RNA was subjected to reverse transcription using Super-
ScriptTM III First-Strand Synthesis System for RT-PCR (Life
Technologies) following manufacturer’s instructions. Resulting
cDNA was used as a template for relative quantitation using the
ABI Prism 7500 Fast Real-Time PCR System (Life Technolo-
gies) as previously described (33). The qPCR results were nor-
malized using Ube2l3 as the reference gene. Primer sequences
are available upon request.
Rota-rod characterization of Plekhg5DEx11-Ex17/DEx11-Ex17
mice
All animals were tested during the light phase of the light-dark
cycle. At least eight control and eight Plekhg5DEx11-Ex17/DEx11-
Ex17 mice were tested three times at each time point. Mice were
placed on a rod rotating at a speed of 5 rpm (Rotamex-5; Colum-
bus Instruments). Then, the speed was increased by 0.5 rpm




Electrophysiological characterization of 6- and 12-month-old
control and Plekhg5DEx11-Ex17/DEx11-Ex17 mice was performed
as previously described (34). All animals were anesthetized
with a mixture of 10 ml/g ketanarkon 100 (1 mg/ml; Streuli)
and 0.1% Rompun (Bayer) in PBS. The left and right sciatic
nerves were stimulated at the sciatic notch and distally at the
ankle via bipolar electrodes with supramaximal square-wave
pulses (5 V) of 0.05 ms and the latencies of the compound
muscle action potentials were recorded.
Motoneuron analysis
Animals were deeply anesthetized with isoflurane and decapi-
tated. The entire lumbar region of the spinal cord was dissected
out and post-fixed in 4% PFA PBS (0.1 M, pH 7.4) solution over-
night at 48C. Tissues were cryoprotected by immersion for 48 h
in a 20% sucrose PBS solution at 48C. Tissues were embedded in
O.C.T (VWR) on dry ice. We then performed experiment as pre-
viously described with few minor modifications (35). Serial sec-
tions (thickness: 16 mm) of the spinal cord were collected and
motoneurons were stained with hematoxylin/eosin. Motoneur-
ons (with a diameter over 25 mm;a-motoneurons) in the ventro-
lateral quarter of both sides were counted every fifth sections for
a total of 20 sections per spinal cord.
Whole mount immunohistochemistry of soleus
and EDL NMJs
Animals were deeply anesthetized with isoflurane and decapi-
tated. The slow-twitch muscle soleus and the fast-twitch
muscle EDL were collected on both sides, pinned on a Sylgard-
coated dish, fixed 30 min in 4% PFA PBS solution and then incu-
bated in a sucrose 20% PBS solution before OCT embedding.
Fifteen micrometer sections were prepared and permeabilized
2 h in a 5% BSA 0.5% Triton PBS solution. Presynaptic compo-
nent of the NMJ and SC morphology was revealed by S100
(1:250; Dako) and a-neurofilament stainings (1:200 NF145;
Millipore) overnight and followed by 2 h incubation with goat
anti-rabbit Alexa 488 secondary antibody (1:200; Invitrogen).
To label the post-synaptic endplates, tissues were then exposed
to a-bungarotoxin CF594 (Biotium) for 1 h. To finish, muscles
sections were washed with PBS and mounted in Mowiol (Calbio-
chem). Sections were imaged with a Zeiss Axiovision. Inner-
vated or denervated endplates were counted on 15 mm
Z-stacks with a ×20 magnification.
SUPPLEMENTARYMATERIAL
Supplementary Material is available at HMG online.
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